Stroke prevention: anti-platelet and anti-thrombolytic therapy.
In patients with TIA or ischemic stroke of noncardiac origin antiplatelet drugs are able to decrease the risk of stroke by 11-15%, and the risk of stroke, MI, and vascular death by 15-22%, but not mortality. Low doses of aspirin (50-325 mg) are as effective as high doses and cause less gastrointestinal side effects. Severe bleeding complications are not dose-dependent. The combination of aspirin with slow release dipyridamole is superior to aspirin alone for stroke prevention. Ticlopidine is superior to aspirin but has slightly more serious adverse effects (neutropenia). It will be replaced by clopidgrel which has a better safety profile. Anticoagulation with an INR between 3.0 and 4.5 is too dangerous. Whether anticoagulation with lower INR is safe and effective is not yet known.
Diener
H C
HC
Professor, Department of Neurology, University of Essen, Germany. h.diener@uni-essen.de
D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D019934:International Normalized Ratio; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D020521:Stroke / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome
D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors